SEC Form 4 · accession 0001543084-16-000005
ARGOS THERAPEUTICS INC · ARGS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sander van Deventer
Director · 10% Owner
Period of report
Sep 30, 2016
Accepted (ET)
Oct 3, 2016 · 11:28 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001105533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 30, 2016 | A | 2,263 | $0.00 | A | 5,057 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person has received a fully vested stock award for shares of the Company's common stock. For calendar year 2016, the Company has elected to make common stock awards in lieu of cash payments of director fees otherwise payable under the director compensation policy. The number of shares of common stock awarded represent the quotient of (A) such director fees divided by (B) the Company's closing stock price on the date awarded, rounded down to the nearest whole share of common stock.